Announcement of call for payment of share subscriptions for the 2025 cash capital increase

 

SEQ_NO  1 Date of announcement 2026/01/23 Time of announcement 17:42:31
Subject
Announcement of call for payment of share
subscriptions for the 2025 cash capital increase
Date of events 2026/01/23 To which item it meets paragraph 51
Statement
1.Date of occurrence of the event:2026/01/23
2.Company name:Excelsior Medical Co.,Ltd.
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office
4.Reciprocal shareholding ratios:Not applicable.
5.Cause of occurrence:The deadline for payment of share subscriptions for
the company’s 2025 cash capital increase expired on 2026/1/23.
As some original shareholders and employees have not yet remitted the
subscription amounts, the company hereby announces this call for payment.
6.Countermeasures:
(1)In accordance with Article 142 and Paragraph 3 of Article 266 of
the Company Act, the call for payment period is set from
2026/1/28 to 2026/3/3 at 3:30 p.m.
(2)Original Shareholders and employees who have not yet made payment
shall complete the payment within the above period in accordance with
the method specified in the original payment notice. Any subscription
rights will be forfeited if payment is not made within the deadline.
(3)For shareholders and employees who make payment during the call period,
after the period has expired and processing by the Taiwan Depository &
Clearing Corporation, the subscribed shares will be credited to the
subscriber’s securities depository account in accordance with the number
of shares subscribed.
(4)Please contact the company’s stock affairs ageny:President Securities
Corporation, Shareholder Services Department(Address: B1, No. 8, Dongxing
Rd., Taipei , Taiwan; TEL: 02-2746-3797).
7.Any other matters that need to be specified (the information disclosure
also meets the requirements of Article 7, subparagraph 9 of the Securities
and Exchange Act Enforcement Rules, which brings forth a significant impact
on shareholders rights or the price of the securities on public companies.):
None.